Aggrecan: a new biomarker for acute type A aortic dissection

Abstract Acute type A aortic dissection (ATAAD) constitutes a life-threatening aortic pathology with significant morbidity and mortality. Without surgical intervention the usual mortality rate averages between 1 and 2% per hour. Thus, an early diagnosis of ATAAD is of pivotal importance to direct th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Karl C. König, Harald Lahm, Martina Dreßen, Stefanie A. Doppler, Stefan Eichhorn, Nicole Beck, Kathrin Kraehschuetz, Sophia Doll, Stefan Holdenrieder, Adnan Kastrati, Rüdiger Lange, Markus Krane
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/26ea50aaeea44803b402552afb394a9d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:26ea50aaeea44803b402552afb394a9d
record_format	dspace
spelling	oai:doaj.org-article:26ea50aaeea44803b402552afb394a9d2021-12-02T17:16:14ZAggrecan: a new biomarker for acute type A aortic dissection10.1038/s41598-021-89653-y2045-2322https://doaj.org/article/26ea50aaeea44803b402552afb394a9d2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-89653-yhttps://doaj.org/toc/2045-2322Abstract Acute type A aortic dissection (ATAAD) constitutes a life-threatening aortic pathology with significant morbidity and mortality. Without surgical intervention the usual mortality rate averages between 1 and 2% per hour. Thus, an early diagnosis of ATAAD is of pivotal importance to direct the affected patients to the appropriate treatment. Preceding tests to find an appropriate biomarker showed among others an increased aggrecan (ACAN) mRNA expression in aortic tissue of ATAAD patients. As a consequence, we investigated whether ACAN is a potential biomarker for diagnosing ATAAD. Mean ACAN protein concentration showed a significantly higher plasma concentration in ATAAD patients (38.59 ng/mL, n = 33) compared to plasma of patients with thoracic aortic aneurysms (4.45 ng/mL, n = 13), patients with myocardial infarction (11.77 ng/mL, n = 18) and healthy volunteers (8.05 ng/mL, n = 12). Cardiac enzymes like creatine kinase MB and cardiac troponin T showed no correlation with ACAN levels in ATAAD patients. Receiver-operator characteristics (ROC) curve analysis for ATAAD patients versus control subjects an optimum discrimination limit of ACAN plasma levels at 14.3 ng/mL with a corresponding sensitivity of 97% and specificity of 81%. According to our findings ACAN is a reliable potential biomarker in plasma samples to detect ATAAD with high sensitivity and specificity.Karl C. KönigHarald LahmMartina DreßenStefanie A. DopplerStefan EichhornNicole BeckKathrin KraehschuetzSophia DollStefan HoldenriederAdnan KastratiRüdiger LangeMarkus KraneNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Karl C. König Harald Lahm Martina Dreßen Stefanie A. Doppler Stefan Eichhorn Nicole Beck Kathrin Kraehschuetz Sophia Doll Stefan Holdenrieder Adnan Kastrati Rüdiger Lange Markus Krane Aggrecan: a new biomarker for acute type A aortic dissection
description	Abstract Acute type A aortic dissection (ATAAD) constitutes a life-threatening aortic pathology with significant morbidity and mortality. Without surgical intervention the usual mortality rate averages between 1 and 2% per hour. Thus, an early diagnosis of ATAAD is of pivotal importance to direct the affected patients to the appropriate treatment. Preceding tests to find an appropriate biomarker showed among others an increased aggrecan (ACAN) mRNA expression in aortic tissue of ATAAD patients. As a consequence, we investigated whether ACAN is a potential biomarker for diagnosing ATAAD. Mean ACAN protein concentration showed a significantly higher plasma concentration in ATAAD patients (38.59 ng/mL, n = 33) compared to plasma of patients with thoracic aortic aneurysms (4.45 ng/mL, n = 13), patients with myocardial infarction (11.77 ng/mL, n = 18) and healthy volunteers (8.05 ng/mL, n = 12). Cardiac enzymes like creatine kinase MB and cardiac troponin T showed no correlation with ACAN levels in ATAAD patients. Receiver-operator characteristics (ROC) curve analysis for ATAAD patients versus control subjects an optimum discrimination limit of ACAN plasma levels at 14.3 ng/mL with a corresponding sensitivity of 97% and specificity of 81%. According to our findings ACAN is a reliable potential biomarker in plasma samples to detect ATAAD with high sensitivity and specificity.
format	article
author	Karl C. König Harald Lahm Martina Dreßen Stefanie A. Doppler Stefan Eichhorn Nicole Beck Kathrin Kraehschuetz Sophia Doll Stefan Holdenrieder Adnan Kastrati Rüdiger Lange Markus Krane
author_facet	Karl C. König Harald Lahm Martina Dreßen Stefanie A. Doppler Stefan Eichhorn Nicole Beck Kathrin Kraehschuetz Sophia Doll Stefan Holdenrieder Adnan Kastrati Rüdiger Lange Markus Krane
author_sort	Karl C. König
title	Aggrecan: a new biomarker for acute type A aortic dissection
title_short	Aggrecan: a new biomarker for acute type A aortic dissection
title_full	Aggrecan: a new biomarker for acute type A aortic dissection
title_fullStr	Aggrecan: a new biomarker for acute type A aortic dissection
title_full_unstemmed	Aggrecan: a new biomarker for acute type A aortic dissection
title_sort	aggrecan: a new biomarker for acute type a aortic dissection
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/26ea50aaeea44803b402552afb394a9d
work_keys_str_mv	AT karlckonig aggrecananewbiomarkerforacutetypeaaorticdissection AT haraldlahm aggrecananewbiomarkerforacutetypeaaorticdissection AT martinadreßen aggrecananewbiomarkerforacutetypeaaorticdissection AT stefanieadoppler aggrecananewbiomarkerforacutetypeaaorticdissection AT stefaneichhorn aggrecananewbiomarkerforacutetypeaaorticdissection AT nicolebeck aggrecananewbiomarkerforacutetypeaaorticdissection AT kathrinkraehschuetz aggrecananewbiomarkerforacutetypeaaorticdissection AT sophiadoll aggrecananewbiomarkerforacutetypeaaorticdissection AT stefanholdenrieder aggrecananewbiomarkerforacutetypeaaorticdissection AT adnankastrati aggrecananewbiomarkerforacutetypeaaorticdissection AT rudigerlange aggrecananewbiomarkerforacutetypeaaorticdissection AT markuskrane aggrecananewbiomarkerforacutetypeaaorticdissection
_version_	1718381189157355520

Aggrecan: a new biomarker for acute type A aortic dissection

Ejemplares similares